CJC-1295 Ipamorelin raises GH and IGF-1 across a multi-day window — here is what the studies actually measured.

The short version

CJC-1295 Ipamorelin is two lab-made peptides used together. One, CJC-1295, is a long-acting copy of the natural signal (GHRH) that tells the pituitary gland to make growth hormone (GH). The other, ipamorelin, hits a second switch — the ghrelin receptor — to trigger a short GH pulse. Used together in research, they push the body to release more of its own GH, which the liver turns into IGF-1, the messenger that carries most of GH's effects.

In healthy adults, one dose of the long-acting form raised GH several-fold for six days or more and IGF-1 for about nine to eleven days ^[1]. People in research-use communities report deeper sleep, faster recovery, more hunger, and some puffiness or numbness — anecdotes, not proof. Neither peptide is approved by the FDA, and the fixed combination has never been tested in a controlled trial. What people report, including the downsides, is laid out on the effects page.

What the numbers show

Start with the cleanest human figure. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma GH two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults aged 21 to 61; after repeat dosing, IGF-1 stayed above baseline for as long as 28 days ^[1]. That multi-day footprint is the whole reason this GHRH analogue exists.

The ipamorelin half is defined by a different headline: selectivity. In rat and swine models it released GH as powerfully as the older peptide GHRP-6, yet — even at doses more than 200 times the amount needed for half-maximal GH release — it did not raise the stress hormones ACTH or cortisol above the level GHRH alone produces ^[2]. It was the first GH secretagogue clean enough to earn that label.

Put the two switches together and the GH response is supra-additive — bigger than the sum of either alone. In normal men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms ^[3]. At the receptor level, co-activating both receptors in transfected cells produced roughly twice the cAMP signal of GHRH alone ^[4].

The honest caveat the headline numbers hide

Every figure above comes from studying one peptide at a time, or from GHRH-plus-GHRP synergy work that used related peptides — not the exact CJC-1295 + ipamorelin pair. The fixed blend has never been evaluated in a controlled clinical trial. Combination claims are inferences: each compound's own literature, plus the general principle that a GHRH signal and a ghrelin-receptor signal add up to more GH together than apart.

The two halves also run on different clocks. CJC-1295 with DAC binds albumin in the blood and lingers for roughly six to eight days; ipamorelin clears within hours. The no-DAC version of CJC-1295, called Mod GRF (1-29), instead acts for only about 30 minutes. Pairing a multi-day agent with a short pulse means net GH exposure for any given protocol is simply not characterized. This is the CJC-1295 Ipamorelin research in one sentence: the single-component data is real and the synergy principle is real, but the blend itself is uncharted.

What this site is

This is an editorial digest, not a clinic and not a store. It reads the peer-reviewed record on CJC-1295 and ipamorelin and lays the measured quantities out plainly: the GH fold-rise, the IGF-1 duration, the half-life split between the DAC and no-DAC forms, the selectivity data. Every quantitative claim maps to a numbered citation on the CJC-1295 Ipamorelin references page.

Neither peptide is FDA-approved for any human use; both are sold only as research chemicals. Both are prohibited at all times in sport under the World Anti-Doping Agency's Section S2 (peptide hormones and GH secretagogues). Nothing here is a dose, a protocol, or a recommendation — the cjc 1295 ipamorelin benefits reported by users and the cited safety cautions are summarized as research and community signal, with the line between the two kept visible.